Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Apr 16;14:2699–2710. doi: 10.2147/OTT.S297209

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2021 Wang et al.

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).

PMC Copyright notice

ZEB1-AS1 knockdown inhibited OSCC progression. (A) A gross look of xenograft tumors. (B, C) The relative expression of ZEB1-AS1 and miR-23a in OSCC xenograft tissues. (D) Tumor volumes were examined at days 3, 7, 14, 21, and 28 (n=6). (E) Tumor weights measured at day 28 (n=6). (F, G) Tumor cell proliferation was detected with IHC using an antibody against Ki-67. (H) The protein levels of vimentin, N-cadherin, and E-cadherin in OSCC xenograft tissues. Data are presented as the means ± SD. *, P < 0.05; ***, P < 0.0001. Scale bar=50μm.

Abbreviation: OSCC, oral squamous cell carcinoma.